VivoSeq
Other

Hepatic Impairment

5

Pipeline Programs↗

22

Active Trials↗

87

Companies Involved↗

Hepatic Impairment is an early-stage landscape with 5 programs across 87 companies. The most active players are AstraZeneca, Pfizer, Roche.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

42/100

Mech. Concentration

100/100

Completion Rate

93/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

2 programs

Phase 1Pfizer logo

Pfizer

1 program

Phase 1Roche logo

Roche

1 program

Phase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

1 program

Phase 1S

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

1 program

Phase 1Novartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

247

clinical trials

Completed204 · 83%
Recruiting13 · 5%
Terminated9 · 4%
Not yet recruiting8 · 3%
Unknown status6 · 2%
Withdrawn6 · 2%
Other1 · 0%

Clinical Trials

Trial Activity

247 trials

A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
Recruiting·Merck & Co. logoMerck & Co.·Phase 1·NCT07219550·58 enrolled
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
Recruiting·Daiichi Sankyo logoDaiichi Sankyo·Phase 1·NCT06740799·12 enrolled
A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment
Recruiting·TTaisho Pharmaceutical Co., Ltd.·Phase 1·NCT07231029·24 enrolled
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
Recruiting·Haisco Pharmaceutical Group Co., Ltd. logoHaisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT07152288·24 enrolled
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
Recruiting·EEdgewise Therapeutics, Inc.·Phase 1·NCT07324616·32 enrolled
Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment
Recruiting·Ascentage Pharma Group Inc. logoAscentage Pharma Group Inc.·Phase 1·NCT07282093·48 enrolled
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
Recruiting·VVir Biotechnology, Inc.·Phase 1·NCT05484206·144 enrolled
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Recruiting·Taiho Oncology, Inc. logoTaiho Oncology, Inc.·Phase 1·NCT04953910·27 enrolled
To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function
Recruiting·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·Phase 1·NCT05747664·24 enrolled
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Liver Function
Recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT07694843·24 enrolled
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics of Inavolisib
Recruiting·Roche logoRoche·Phase 1·NCT07144111·32 enrolled
A Phase 1 Open-Label Study to Assess the Pharmacokinetics of Mirdametinib and Its Metabolite PD-0315209 in Participants With Impaired Hepatic Function and Participants With Normal Hepatic Function
Recruiting·SSpringWorks Therapeutics, Inc.·Phase 1·NCT06997276·32 enrolled
A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT07546760·28 enrolled
Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment
Active, not recruiting·GGan & Lee Pharmaceuticals.·Phase 1·NCT07193147·36 enrolled
Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function
Not yet recruiting·Jiangsu Hansoh Pharmaceutical Co., Ltd. logoJiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT06823258·32 enrolled
Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)